Miach Orthopaedics, Inc.
                                                                                                                                    
                                                                                                United States
                                                 -                                                 Westborough, Massachusetts
                                                                                            
                                                                                    - 04/04/2024
 - Series B
 - $20,000,000
 
Miach Orthopaedics is transforming anterior cruciate ligament tear treatment with the BEAR® Implant
- Industry Medical Equipment Manufacturing
 - Website https://www.miachortho.com/
 - LinkedIn https://www.linkedin.com/company/miachortho/
 
Related People
Patrick McBrayerFounder
                                                    
                                                                                                                United States -
                                                         Westborough, Massachusetts
                                                    
                                                Patrick A. McBrayer
President and Chief Executive Officer
pmcbrayer@miachortho.com
215-530-0503
Patrick McBrayer joined Miach Orthopaedics as president and chief executive officer in 2022. He has more than 35 years of experience leading companies in orthopaedics and regenerative medicine and has also been an advisor to medical device companies in spine, orthopaedics and biotechnology.
 
McBrayer has served as president and CEO of multiple companies in the orthopaedic and regenerative medicine industries and brings a wealth of experience in both private equity placements and public offerings. Prior to joining Miach, McBrayer served as president and CEO of ACell, AxioMed Spine Corporation, Exogen and Osteotech; CEO of Xylos Corporation; and co-founder of Transave (now Insmed). He is a recipient of the Thomas Alva Edison Patent Award for a market-leading biological implant for bone repair. Earlier in his career, McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.
 
He is a graduate of the United States Military Academy at West Point and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. 
                                Vesence |  $9,000,000  | (Oct 30, 2025)
                                Sparrow BioAcoustics |  $10,000,000  | (Oct 30, 2025)
                            
                                Reflectiz |  $22,000,000  | (Oct 30, 2025)
                            
                                    
                                    
                                    
                                    
                                    
                                            
                                                
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                
                                                    
                                                
                                                
                                                
                                                    
                                                
                                                
                                                    
                                                
                                                    
                                                
                                                
                                                                        
                                Mem0 |  $24,000,000  | (Oct 30, 2025)
                                                                        
                                Valthos |  $30,000,000  | (Oct 30, 2025)
                                                                        
                                Mondra |  $13,206,500  | (Oct 30, 2025)
                                                                        
                                hoop.dev |  Undisclosed Amount  | (Oct 30, 2025)
                                                                        
                                IORGANBIO |  $2,000,000  | (Oct 30, 2025)
                                                                        
                                FrontlineIQ |  $3,300,000  | (Oct 30, 2025)
                                                                        
                                Homecourt |  $8,000,000  | (Oct 30, 2025)
                                                                        
                                VentureMed Inc. |  $28,000,000  | (Oct 30, 2025)
                                                                        
                                Recess |  $30,000,000  | (Oct 30, 2025)